BFC Planning’s Core Laboratories CLB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.59K Buy
267
+58
+28% +$671 ﹤0.01% 2932
2026
Q2
$2.44K Hold
209
– – ﹤0.01% 2935
2026
Q1
$3.51K Hold
209
– – ﹤0.01% 2438
2025
Q4
$3.35K Hold
209
– – ﹤0.01% 2480
2025
Q3
$2.58K Hold
209
– – ﹤0.01% 2402
2025
Q2
$2.41K Buy
209
+102
+95% +$1.21K ﹤0.01% 2262
2025
Q1
$1.6K Hold
107
– – ﹤0.01% 2348
2024
Q4
$1.85K Hold
107
– – ﹤0.01% 2298
2024
Q3
$1.98K Buy
+107
New +$2.15K ﹤0.01% 2281

Other funds holding CLB

BFC Planning's CLB Position: Q3 2026 in Review

BFC Planning increased its Core Laboratories (CLB) stake by 28% in Q3 2026, buying an estimated $671 and bringing the position to 267 shares worth $2.59K. The position accounts for ﹤0.01% of the portfolio, ranked #2932.

BFC Planning first reported a position in CLB in Q3 2024 and has held it in 9 quarters since. The position peaked at $3.51K in Q1 2026. 131 funds tracked by Wall St. Rank hold CLB as of Q3 2026.

  • BFC Planning held 267 shares of Core Laboratories worth $2.59K as of Q3 2026.
  • BFC Planning bought 58 Core Laboratories shares in Q3 2026, an estimated $671.
  • Core Laboratories made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #2932 holding.
  • BFC Planning first reported a position in Core Laboratories in Q3 2024 and has held it in 9 quarters since.
  • BFC Planning's Core Laboratories position peaked at $3.51K in Q1 2026.
  • 131 funds tracked by Wall St. Rank held Core Laboratories as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.